Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2015 Jun 24

PMID 26102068

Citations 20

Authors

Jinwen Liu

Meijuan Zou

Hongyu Piao

Yi Liu

Bo Tang

Ying Gao

Ning Ma

Gang Cheng

Affiliations

Soon will be listed here.

Abstract

Solid dispersions are a useful approach to improve the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). The aim of this study was to improve the physicochemical properties and bioavailability of a poorly water-soluble aprepitant by preparation of solid dispersions. The solid dispersions were characterized by dissolution, FTIR, XRPD, DSC, SEM and pharmacokinetic studies in rats. The dissolution rate of the aprepitant was significantly increased by solid dispersions, and XRD, DSC, and SEM analysis indicated that the aprepitant existed in an amorphous form within the solid dispersions. The result of dissolution study showed that the dissolution rate of SDs was nearly five-fold faster than aprepitant. FTIR spectrometry suggested the presence of intermolecular hydrogen bonds between the aprepitant and polymer. Pharmacokinetic studies in rats indicated that the degree drug absorption was comparable with that of Emend®. Aprepitant exists in an amorphous state in solid dispersions and the solid dispersions can markedly improve the dissolution and oral bioavailability of the aprepitant. The AUC0-t of the SDs was 2.4-fold that of the aprepitant. In addition, the method and its associated techniques are very easy to carry out.

Citing Articles

Oral Bioavailability Enhancement of Poorly Soluble Drug by Amorphous Solid Dispersion Using Sucrose Acetate Isobutyrate.

Mohamed E, Dharani S, Khuroo T, Nutan M, Cook P, Arunagiri R AAPS PharmSciTech. 2024; 25(7):202.

PMID: 39237685 DOI: 10.1208/s12249-024-02924-5.

Preparation of Erlotinib hydrochloride nanoparticles (anti-cancer drug) by RESS-C method and investigating the effective parameters.

Bazaei M, Honarvar B, Esfandiari N, Sajadian S, Aboosadi Z Sci Rep. 2024; 14(1):14955.

PMID: 38942802 PMC: 11213895. DOI: 10.1038/s41598-024-64477-8.

Advances in the research and application of neurokinin-1 receptor antagonists.

Hong X, Ma J, Zheng S, Zhao G, Fu C J Zhejiang Univ Sci B. 2024; 25(2):91-105.

PMID: 38303494 PMC: 10835208. DOI: 10.1631/jzus.B2300455.

A Novel Semi-Solid Self-Emulsifying Formulation of Aprepitant for Oral Delivery: An In Vitro Evaluation.

Nazli H, Mesut B, Akbal-Dagistan O, Ozsoy Y Pharmaceutics. 2023; 15(5).

PMID: 37242751 PMC: 10222508. DOI: 10.3390/pharmaceutics15051509.

Synthesis, Structural Elucidation, and Anti-Inflammatory Activity of a Water-Soluble Derivative of Arctiin.

Xu X, Huang X, Zheng Y, Wang X, Xie J, Liu S Molecules. 2023; 28(4).

PMID: 36838775 PMC: 9961579. DOI: 10.3390/molecules28041789.

References

Pouton C . Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000; 11 Suppl 2:S93-8. DOI: 10.1016/s0928-0987(00)00167-6. View

Muller R, Jacobs C, Kayser O . Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001; 47(1):3-19. DOI: 10.1016/s0169-409x(00)00118-6. View

Cocquyt V, Van Belle S, Reinhardt R, Decramer M, OBrien M, Schellens J . Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001; 37(7):835-42. DOI: 10.1016/s0959-8049(00)00416-0. View

Babu G, Prasad C, Murthy K . Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine. Int J Pharm. 2002; 234(1-2):1-17. DOI: 10.1016/s0378-5173(01)00925-5. View

Verheyen S, Blaton N, Kinget R, van den Mooter G . Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm. 2002; 249(1-2):45-58. DOI: 10.1016/s0378-5173(02)00532-x. View

Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K . The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004; 285(1-2):135-46. DOI: 10.1016/j.ijpharm.2004.08.001. View

Olver I, Shelukar S, Thompson K . Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine. 2007; 2(1):13-8. PMC: 2673828. DOI: 10.2147/nano.2007.2.1.13. View

Vasconcelos T, Sarmento B, Costa P . Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007; 12(23-24):1068-75. DOI: 10.1016/j.drudis.2007.09.005. View

Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R . Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm. 2008; 34(11):1209-18. DOI: 10.1080/03639040802005024. View

10.

Wu D, Paul D, Zhao X, Douglas S, Barrett J . A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in.... J Pharm Biomed Anal. 2009; 49(3):739-45. PMC: 2883891. DOI: 10.1016/j.jpba.2008.12.005. View

11.

Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman J . Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm. 2010; 76(1):95-104. DOI: 10.1016/j.ejpb.2010.05.009. View

12.

Singare D, Marella S, Gowthamrajan K, Kulkarni G, Vooturi R, Rao P . Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm. 2010; 402(1-2):213-20. DOI: 10.1016/j.ijpharm.2010.09.041. View

13.

Linn M, Collnot E, Djuric D, Hempel K, Fabian E, Kolter K . Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci. 2011; 45(3):336-43. DOI: 10.1016/j.ejps.2011.11.025. View

14.

Ridhurkar D, Ansari K, Kumar D, Kaul N, Krishnamurthy T, Dhawan S . Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm. 2012; 39(11):1783-92. DOI: 10.3109/03639045.2012.737331. View

15.

Riekes M, Kuminek G, Schneider Rauber G, Maduro de Campos C, Bortoluzzi A, Stulzer H . HPMC as a potential enhancer of nimodipine biopharmaceutical properties via ball-milled solid dispersions. Carbohydr Polym. 2013; 99:474-82. DOI: 10.1016/j.carbpol.2013.08.046. View

16.

Wang X, Li L, Huo W, Hou L, Zhao Z, Li W . Characterization and Stability of Tanshinone IIA Solid Dispersions with Hydroxyapatite. Materials (Basel). 2017; 6(3):805-816. PMC: 5512800. DOI: 10.3390/ma6030805. View

17.

Navari R, Reinhardt R, Gralla R, Kris M, Hesketh P, Khojasteh A . Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999; 340(3):190-5. DOI: 10.1056/NEJM199901213400304. View